Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars

Phase 4

Completed

• Conditions: Scars
• Interventions: Drug: Dermatix Q

• Registration Number: NCT00450775
• Lead Sponsor: Innovative Medical

Brief Summary

The purpose of this study is to evaluate the efficacy and patient acceptance of Dermatix Q for the prevention and treatment of scarring.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-03
• Study First Submitted: 2007-03-20
• Study First Submitted QC: 2007-03-21
• Study First Posted: 2007-03-22
• Primary Completion: 2008-03
• Study Completion: 2008-03
• Status Verified: 2008-09
• Last Update Submitted: 2008-09-23
• Last Update Posted: 2008-09-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Female or male patients at least 18 years of age
• Patients who are at serious risk of hypertrophic scarring (due to family history, race, recent surgery, etc)
• Able and willing to provide informed consent and likely to complete all study visits
• All Fitzpatrick skin types will be evaluated

Exclusion Criteria

• Known contraindications to Dermatix or any of its components
• Age of scar is > 4 months
• Keloid scars (scars with increased fibroblastic activity that has exceeded the boundaries of the original scar)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	Dermatix Q	-

Primary Outcome Measures

Name	Time	Method
efficacy	1 yr

Secondary Outcome Measures

Name	Time	Method
patient acceptance	1 yr

Trial Locations

Locations (1)

Dadeland Dermatology; 🇺🇸 Coral Gables, Florida, United States